The DREAMM-7 trial showed belantamab mafodotin combination significantly improved overall survival in relapsed/refractory multiple myeloma compared to daratumumab-based therapy. The investigational ...
Based on favorable PFS and manageable safety profile, belantamab mafodotin in combination with bortezomib plus dexamethasone has potential to become a new standard of care in the second line or later ...
CHICAGO — In this video, Adam Cohen, MD, discussed findings from the DREAMM-7 and DREAMM-8 trials presented at ASCO Annual Meeting. The trials combined belantamab mafodotin (Blenrep, GSK) with ...
DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination; benefit seen early and maintained through follow-up Data build on findings ...
At the American Society of Clinical Oncology (ASCO) annual meeting, positive findings were presented on two phase III trials -- DREAMM-7 and DREAMM-8-- testing belantamab mafodotin (Blenrep) in ...
Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024. Please provide your key takeaways from this study.How might these findings impact the management of ...
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free survival (PFS) Median PFS not yet reached at 21.8 months median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback